C2N Diagnostics’ Post

Join me at the @7th_German_Mass_Cytometry_Forum tomorrow to discuss the latest updates in my research. Looking forward to meaningful discussions there! #MassCytometry #ResearchUpdate yEFIS DGFI Young Immunologists TIPAT

👨🔬Meet Dr. Ben J. Gu, Principal Science and Head of the Innate Phagocytosis Lab at the Florey Institute, University of Melbourne. Established in 2012, his lab focuses on pioneering novel diagnostic tools and therapeutic drugs for Alzheimer’s disease. We're honored to support their groundbreaking research with our INFORS HT bioreactors. "Our lab has been using INFORS HT bioreactors for nearly 10 years, from Minifors to Labfors. With their state-of-the-art design, we can easily optimize culture conditions for various applications. The stability and reliability of each batch are unmatched, allowing us to prepare our work as scheduled." - Dr. Ben Gu, Innate Phagocytosis Lab. 🔗Want to learn more about our bench-top bioreactors? https://ow.ly/F4RK50SnbTu #InforsHT #Bioreactors #ScientificInnovation #LabEfficiency #ResearchSupport #AlzheimersResearch #CustomerSatisfaction #ScientificBreakthroughs

Looking to make your Cytokine Release Assays faster and more reliable??? In this video Dr. Jean Dunne shares key insights from her research on #cytokine measurement to evaluate #cellularresponse in both clinical and research environments using the #ELLA https://lnkd.in/e_cEQf85

What were the main scientific highlights and key learnings from #EuroPCR 2024, and what should you know about impact on practice? In this short session replay, Davide Capodanno summarises his key takeaways from this year's Course ➡ https://lnkd.in/d5XsMnQW (open access). Nieves Gonzalo Nicolas Dumonteil Thomas Cuisset #interventionalcardiology #clinicaltrials #latebreakingscience #trialupdates

🔬New Article Co-authored by UNC and Duke Researchers Dougald Monroe, PhD, from UNC Department of Medicine and Ammon Fager, MD, PhD, from Duke Department of Medicine have co-authored a new article titled, “Stopping the bleed when the platelets don’t stick.” The publication details a bifunctional antibody that brings factor VIIa, which kickstarts platelet activation, to the surface of activated platelets. The antibody is currently in clinical trials for the treatment of a platelet adhesion disorder called Glanzmann thrombasthenia. https://ow.ly/MNJv50QHkWn #UNC #DeptofMed #unchealth #platelets #antibody #medicalresearch #clinicaltrials #Glanzmannthrombasthenia #medicalarticle

Our Study titled "Effect of Everolimus on Prognosis of Neurofibromatosis Type 1 Lesions: A Systematic Review and Meta Analysis" has been published online Important Highlights: • Explored everolimus, an mTOR inhibitor, for its effect on NF-1 lesion size via meta-analysis. • Four phase II single arm trials with 83 patients showed no significant effect of oral everolimus on lesion size reduction. • Safety discrepancies across studies raise concerns about everolimus' overall safety in NF-1 patients. • Emphasizes the necessity for more research, personalized treatments, and larger standardized trials in NF-1. you can read the full text here: https://lnkd.in/dMDPY_g2 Thanks to Global Alliance of Young Researchers thanks to Dr Mostafa Meshref , Dr Abdulqadir Nashwan for their great Efforts LinkedIn Ahmed Nada #Everolimus #Research #NF1

#Electrophysiology community, recent data from the EU-PORIA sub-analysis on the impact of body mass index on #PFA of #AFib have been presented at #EHRA2024. Get an exclusive listen to Prof. Schmidt to learn more about the registry and its key learnings! To learn more on FARAPULSE™ PFA extensive clinical evidence: https://lnkd.in/dDdeWaUC #BSCEMEA

Have you heard about ATHN Transcends? ATHN Transcends is ATHN’s flagship research study. Transcends is guided by, written by, and supervised by experienced hematologists in an effort to answer clinically significant research questions. Want to get involved? https://lnkd.in/dAJrqm8S

In this video, we delve into the fascinating world of chitinase 3 like protein 1 (CHI3L1) and its potential as a diagnostic tool for hepatic fibrosis. Hepatic fibrosis is a common liver disease that affects millions of people worldwide, but current diagnostic methods are often unreliable and invasive. That's where CHI3L1 comes in – recent research has shown that it may be a promising biomarker for hepatic fibrosis, offering a non-invasive and accurate way to diagnose and monitor the disease. Through our PowerPoint presentation, we'll explore the science behind CHI3L1 and hepatic fibrosis, examining the latest research and findings in the field. We'll cover topics such as the biology of CHI3L1, the mechanisms of hepatic fibrosis, and the potential clinical applications of CHI3L1 as a diagnostic tool. Our presentation is based on a thorough research paper, with insights and conclusions drawn from a variety of sources in the scientific community. Whether you're a medical professional, a researcher, or simply interested in the latest advances in biomedical science, this video is sure to provide you with valuable insights and knowledge. So sit back, relax, and join us on a journey through the exciting world of CHI3L1 and hepatic fibrosis diagnosis. #hepaticfibrosis #hepatitis #tumourmarkers #chitinase #HCC #liverdiseases #liverdisorders #referenceinterval #referencevalue #populationspecific #earlydiagnosis #noninvasivemarker #prevention #cure #Pakistan https://lnkd.in/ezCCtjmT

CASE STUDY: An example of how large-scale generation of iPSC-derived models can be streamlined to success. This study by Karin Langenberg shows how we developed a scalable process for skeletal muscle cells, highlighting a cost-efficient approach and the use of high-content imaging for quality assessment. Enhance your understanding of iPSC technology and its applications to advance therapeutic research. Download the full case study here: https://lnkd.in/dpBqEsBQ #Ncardia #iPSC #CaseStudy